Source comparison
MK-677 vs Exogenous Growth Hormone: Cost, Safety, Mechanism Comparison
Mechanism Ghrelin receptor agonist. Stimulates endogenous GH pulsatile release Direct GH replacement. Suppresses endogenous production via negative feedback MK-677 preserves natural pulsatility; rhGH creates flat supraphysiological levels IGF-1 Elevation 60–90
This comparison does not assign a generated winner or score.
- Mechanism
- Ghrelin receptor agonist. Stimulates endogenous GH pulsatile release
- Direct GH replacement. Suppresses endogenous production via negative feedback
- MK-677 preserves natural pulsatility; rhGH creates flat supraphysiological levels
- IGF-1 Elevation
- 60–90% increase from baseline, sustained 24 hours per dose
- 150–300% increase dose-dependent, peaks 6–8 hours post-injection
- MK-677 produces moderate, sustained elevation; rhGH creates acute spikes
- Dosing Frequency
- Once daily oral administration (20–25mg standard research dose)
- Daily subcutaneous injection (2–4 IU typical performance dose)
- MK-677 compliance is higher due to oral route and once-daily schedule
- Cost (Monthly)
- Research-grade MK-677 ranges $80–$150/month at 25mg daily
- Pharmaceutical rhGH ranges $800–$1,500/month at 2–4 IU daily
- MK-677 is 85–95% less expensive for comparable IGF-1 outcomes
- Side Effect Profile
- Transient water retention, mild fasting glucose elevation (5–8%), increased appetite
- Joint pain, carpal tunnel syndrome, insulin resistance risk at prolonged high doses
- MK-677 side effects resolve with dose titration; rhGH risks scale with dose and duration
- Lean Mass Gain (12 weeks, trained population)
- 2.8–4.1kg average when combined with resistance training 4–5x/week
- 4.5–6.2kg average in similar training conditions
- rhGH produces 30–40% greater absolute mass gain but at 10× the cost